Equity Events is a Brisbane based company which specialises in organising investment events for the mining, energy, exploration and industrial sectors. Each year the host the very successful Noosa Mining Conference.
Copyright 2024 – Finance News Network
Source: Finance News Network
13 Mar 2020 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO, Dr Michael Baker talks 1H20 results progress with the company's lead product Zolpimist, the spay version of Sanofi’s blockbuster insomnia drug Ambien and focus for 2020.
Read More03 February 2021 - Nyrada Limited (ASX:NYR) CEO James Bonnar talks about the company's collaboration agreement with the Walter Reed Army Institute of Research and UNSW into the study of a first-ever pharmaceutical treatment for traumatic brain injury, a top health priority for the military.
Read More30 Jul 2024 - Dave O'Neill - Managing Director - American West Metals (ASX:AW1) ) is an Australian clean energy mining company focused on growth through the discovery and development of major base metal mineral deposits in Tier 1 jurisdictions of North America.
Read More16 Jan 2025 - Off the Chain Capital's CIO Brian Estes discusses Bitcoin's ethical implications, investment metrics, and future outlook.
Read More24 Mar 2021 - Shaw and Partners Chief Investment Officer Martin Crabb discusses historical precedence for recovering from government spending, the possible rise of interest rates, labour market data, and investment strategies in this environment.
Read More01 Aug 2025 - AI platform revolutionising pharmaceutical quality control
Read More7 July 2020 - Renergen (ASX:RLT) Managing Director, Stefano Marani talks about its high concentration of helium from Phase 1 drill results at its Virginia Gas Field in the Karoo Basin, South Africa.
Read More20 Mar 2023 - Magontec Limited (ASX:MGL) Executive Chairman and CEO Nicholas Andrews discusses the magnesium industry, drivers of demand, China, supply chains into the US and Europe, and recent financial results.
Read More25 Feb 2020 - Noxopharm Limited (ASX:NOX) Chief Medical Officer, Dr Gisela Mautner, talks about results from the company's LuPIN trial in prostate cancer, evaluating its lead product candidate, Veyonda, in combination with 177Lu-PSMA-617, a radiopharmaceutical therapy, in 56 patients with late-stage prostate cancer.
Read More18 May 2022 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow provides an update on clinical trial progression, and discusses recent agreements with WuXi Advanced Therapies and Be The Match BioTherapies.
Read More
